- Because overall influenza vaccination coverage in U.S. children (age, 2-17 years) remains suboptimal, the Advisory Committee on Immunization Practices (ACIP) is including Quadrivalent Live Attenuated Influenza Vaccine (LAIV4) as an option for the 2018-2019 season.
Why this matters
- Data demonstrate that LAIV4 effectiveness against A(H1N1)pdma09-like virus A/Slovenia/2903/2015 is significantly higher than for its predecessor A/Bolivia/559/2013, with seroconversion rates in children comparable with those obtained in response to prepandemic influenza H1N1 LAIV strains.
- For 2018-2019 season, clinicians can choose any licensed, age-appropriate vaccine (inactivated influenza vaccine [IIV], recombinant influenza vaccine, LAIV4).
- Data from 2010-2011 through 2016-2017 seasons demonstrate effectiveness of LAIV3 and its replacement LAIV4 against influenza B, A(H3N2) viruses comparable with IIV vaccines.
- Due to poor effectiveness in U.S. children against A(H1N1), ACIP did not recommend LAIV4 for use during the 2017-2018 season.
- New data demonstrate that LAIV4 influenza A(H1N1)pdm09-like virus A/Slovenia/2903/2015 was shed by a higher proportion of children from days 4 to 7 after the first vaccine dose.
- LAIV4 also induced significantly higher antibody responses vs its predecessor A/Bolivia/559/2013.
- Additionally, the manufacturer will use new methods to evaluate/select candidate vaccine viruses for inclusion, present those to FDA, and analyze replicative fitness in human nasal epithelial cell culture.